Persian

PerkinRa®

Anakinra

Category: Rheumatology

PerkinRA® contains the active substance which is named Anakinra (an immunosuppressive agent). Cytokines are proteins synthesized in body and coordinate inter-cellular communication, and contribute to controlling cell activities.

General Information

Vitiligo

In Rheumatoid Arthritis (RA), Cryopyrin- Associated Periodic Syndrome (CAPS) and in Still’s Disease, your body produces large amounts of cytokine, called Interleukin-1, which causes harmful effects such as inflammation and development of disease symptoms. Your body generally produces proteins to suppress the harmful impacts of Interleukin1-; Anakinra, the active substance of PerkinRA®, does the same work as these suppressing proteins. Anakinra has been manufactured by DNA technology using E.coli microorganism.

General Information

PerkinRA® is prescribed for the following diseases:

• Cryopyrin-associated periodic syndromes (CAPS)

• Neonatal-Onset Multisystem Inflammatory Disease (NOMID), also known as Chronic Infantile Neurologic Cutaneous and Articular Syndrome (CINCA).

• Muckle - Wells Syndrome (MWS)

• Familial Cold auto- Inflammatory Syndrome (FCAS)

More About PerkinRa®

What you need to know before you use PerkinRA®?

Do not use PerkinRA® in following cases:

• If you are allergic to anakinra

• If you are allergic to other medicines manufactured by DNA technology using E.coli microorganism.

• If the blood test shows you are suffering from neutropenia disease (reduction in white blood cells).

Does PerkinRA® have any drug interaction?

Mechanism of action of PerkinRA®:

PerkinRA® blocks the biologic activity of IL-1 alpha and beta by competitively inhibiting IL-1 binding to the interleukin-1 type I receptor (IL-1RI), which is expressed in a wide variety of tissues and organs. IL-1 production is induced in response to inflammatory stimuli and mediates various physiologic responses including inflammatory and immunological responses. IL-1 has a broad range of activities including cartilage degradation by its induction of the rapid loss of proteoglycans, as well as stimulation of bone resorption. The levels of the naturally occurring IL-1Ra in synovium and synovial fluid from RA patients are not sufficient to compete with the elevated amount of locally produced IL-1.

Physico-chemical characteristics:

Dosage form: prefilled syringe 100 mg/0.67 ml

Color: colourless-to-white solutions

Storage: 2° to 8°C (36° to 46°F)

For adverse event report and contact with patient support unit

Click Here

First slide

Published Articles